Press releases
Interim report May 1 - July 31 2010
September 9 2010Further reading »
Approval for Paccal Vet with EMA begins
August 31 2010Further reading »
Study shows good tolerance for Doxophos Vet
August 30 2010Further reading »
Two thirds of the patients enrolled in the study
August 17 2010Further reading »
Paccal Vet's Phase III study submitted to FDA
August 4 2010Further reading »
Oasmia enters into SEK 75 million SEDA-agreement
July 22 2010Further reading »
The Oasmia share is now traded on NASDAQ OMX
June 24 2010Further reading »
Oasmia admitted to trading on NASDAQ OMX Stockholm
June 17 2010Further reading »
Oasmia appoints Remium as liquidity provider
June 10 2010Further reading »
Year-end report May 1 2009 - April 30 2010
June 10 2010Further reading »
Preliminary results show Phase III met endpoint
May 4 2010Further reading »
Björn Björnsson nominated as new Board Member
May 3 2010Further reading »
Oasmia closes agreement with Nippon Zenyaku Kogyo.
April 22 2010Further reading »
Last patient out for Paccal® Vet Phase III study
March 1 2010Further reading »
Interim report May 1, 2009 - January 31, 2010
February 26 2010Further reading »
Oasmia changes report publication date
December 28 2009Further reading »
Oasmia publishes Interim Report for May - Oct
December 10 2009Further reading »
Oasmia starts clinical studies with Doxophos® Vet
December 9 2009Further reading »
Oasmia carries out private placement
November 5 2009Further reading »
Oasmia successfully concludes enrolment
October 21 2009Further reading »
Communiqué from Annual General Meeting
September 28 2009Further reading »
Interim report May 1 - July 31 2009
September 10 2009Further reading »
Oasmia’s rights issue fully subscribed
August 28 2009Further reading »
Notice of Annual General Meeting 2009
August 27 2009Further reading »
Oasmia SA’s commitment in rights issue
August 25 2009Further reading »
Oasmia publishes prospectus
August 3 2009Further reading »
Oasmia announces distribution agreement
July 13 2009Further reading »
Oasmia announces license agreement with Abbott
July 10 2009Further reading »
Oasmia proposes new share issue
June 24 2009Further reading »
FDA grants Paclical® Orphan Drug Designation
April 14 2009Further reading »
Oasmia: FDA grants Paccal Vet Minor Use status
April 1 2009Further reading »
Interim Report May 2008 - January 2009
March 19 2009Further reading »
Phase III study generates great interest in Europe
February 11 2009Further reading »
Oasmia aims for global registration of Paccal Vet
February 5 2009Further reading »
Communiqué from Extraordinary General Meeting
February 2 2009Further reading »
Promising clinical results for Paclical
January 27 2009Further reading »
Solid scientific evidence for Paccal Vet
January 21 2009Further reading »
FDA grants Expedited Review Status to Paclical Vet
January 14 2009Further reading »
Call to Extraordinary General Meeting
January 12 2009Further reading »
Oasmia appoints market maker
December 1 2008Further reading »
Oasmia changes marketplace
October 1 2008Further reading »
Notice of Annual General Meeting
August 14 2008Further reading »
Oasmia expands license agreement for Paclical Vet
June 25 2008Further reading »
New license agreement with Orion Corporation
March 26 2008Further reading »
Phase III results presented in Copenhagen
March 3 2008Further reading »
Oasmia presents Phase III-results in Denmark
January 31 2008Further reading »
Final advice for Paclical Phase III program
January 29 2008Further reading »
Oasmia announces licensing agreement
November 27 2007Further reading »
Oasmia presented in Florida
November 5 2007Further reading »
Oasmia presents in USA
October 9 2007Further reading »
Oasmia in Barcelona
September 27 2007Further reading »
Great interest for Oasmia in Budapest
September 20 2007Further reading »
Oasmia publishes Listing Prospectus
September 17 2007Further reading »
Oasmia to NGM Equity
September 17 2007Further reading »
Oasmia presents in Budapest
June 19 2007Further reading »
Status – listing of Oasmia
May 29 2007Further reading »
Very good clinical results for Paclical®
April 16 2007Further reading »
Unique results for cancer drug
March 27 2007Further reading »
New drug for treatment of cancer in dog
March 13 2007Further reading »
Oasmia confirms Orphan Drug Designation
November 30 2006Further reading »
Oasmia obtains Orphan Drug designation
November 15 2006Further reading »
